Nonsurgical rhinoplasty using the hyaluronic acid filler VYC‐25L: Safety and patient satisfaction in a retrospective analysis of 492 patients

Abstract

BackgroundAesthetic treatment of the nose with hyaluronic acid (HA) fillers is increasingly popular but carries a small risk of major complications. Large patient cohorts are required to better understand this risk.AimsTo evaluate safety and patient satisfaction in a large series of nonsurgical rhinoplasty treatments with the HA filler, VYC‐25L, in “real world” clinical practice.MethodsThis was a retrospective analysis of consecutive adult patients undergoing nonsurgical rhinoplasty with VYC‐25L by a single injector between January 2020 and July 2022. All patients received initial treatment (typically ~0.3–0.5 mL of filler) and touch‐up at 4–6 weeks (~0.1–0.3 mL). Safety data were collected throughout a mean follow‐up of 11.1 months. Patient satisfaction was assessed using the FACE‐Q Satisfaction with Nose and Satisfaction with Outcome questionnaires.ResultsA total of 492 patients were included (984 treatment sessions including touch‐ups). Of these, 467 (94.9%) were female and the mean age was 30.0 years. All treatments were associated with early transient edema; other adverse events included bruising (n = 123; 25%), residual asymmetry (n = 18; 3.7%), and suspected localized vascular occlusion (n = 3; 0.6%). The latter cases were easily resolved with hyaluronidase injection plus oral steroid and aspirin. No patients experienced infection, necrosis, blindness, lumps, granuloma, or delayed‐onset nodules. Mean Rasch‐transformed FACE‐Q scores were 90.2% for Satisfaction with Nose and 99.2% for Satisfaction with Outcome.ConclusionsIn a large cohort of patients treated in routine practice based on a systematic approach, nonsurgical rhinoplasty with VYC‐25L was safe and effective.

Nonsurgical Rhinoplasty: Systematic Review

“…Notably, there were no instances of infection, necrosis, blindness, lumps, granuloma, or delayed-onset nodules. 9 The analysis also revealed high levels of patient satisfaction with the treatment, as assessed through the FACE-Q Satisfaction with Nose and FACE-Q Satisfaction with Outcome questionnaires. Mean Rasch-transformed scores were 90.2% and 99.2%, respectively, equating to untransformed scores of 39/40 for Satisfaction with Nose and just under 24/24 for Satisfaction with Outcome.…”

“…The mean follow-up duration was 11.1 months. 9 Regarding complications, all treatments were associated with transient edema lasting approximately 7-10 days. Other adverse events included bruising (n = 123; 25.0%), residual asymmetry (n = 18; 3.7%), and suspected localized vascular occlusion (n = 3; 0.6%).…”